In a randomized Phase III trial, the addition of bevacizumab to lomustine did not improve overall survival in patients with recurrent glioblastoma compared to lomustine alone.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content